Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
Guidance, NICE advice and quality standards
In development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (1 active)
Skip to results
Filter by title or keyword
Filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (5)
Type
Type
Guidance (302)
Guidance programme
(
1 selected
)
Guidance programme
Clinical guidelines (27)
Diagnostics guidance (9)
Health technology evaluations (11)
Highly specialised technologies guidance (8)
Interventional procedures guidance (10)
Medical technologies guidance (11)
NICE guidelines (30)
Public health guidelines (1)
Technology appraisal guidance (302)
Apply filters
Showing 1 to 25 of 302
Sort by
Title
Date
Apply sorting
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]
Technology appraisal guidance
TBC
Abaloparatide for treating osteoporosis in postmenopausal women [ID882]
Technology appraisal guidance
7 August 2024
Abatacept for preventing moderate to severe acute graft-versus-host disease after haematopoietic stem cell transplant in people 6 years and over [ID6185]
Technology appraisal guidance
TBC
Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230]
Technology appraisal guidance
TBC
Abicipar pegol for treating wet age-related macular degeneration ID1533
Technology appraisal guidance
TBC
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]
Technology appraisal guidance
TBC
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer [ID6368]
Technology appraisal guidance
11 December 2024
ALXN1840 for treating Wilson disease TS ID 9950
Technology appraisal guidance
TBC
Alzheimer's disease (early) - gantenerumab [ID6142]
Technology appraisal guidance
TBC
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer ID5110
Technology appraisal guidance
TBC
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer ID6256
Technology appraisal guidance
TBC
Amyotrophic lateral sclerosis - SAR443820 [ID6386]
Technology appraisal guidance
TBC
Anhydrous sodium thiosulfate (Pedmarqsi) for preventing ototoxicity caused by cisplatin chemotherapy in people aged 1 month to 17 years with localised solid tumours [ID1001]
Technology appraisal guidance
TBC
Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]
Technology appraisal guidance
TBC
Asunercept for treating glioblastoma [1301]
Technology appraisal guidance
TBC
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701
Technology appraisal guidance
TBC
Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]
Technology appraisal guidance
TBC
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]
Technology appraisal guidance
TBC
Atezolizumab for untreated advanced or recurrent non-small cell lung cancer when platinum-doublet chemotherapy is unsuitable [ID6218]
Technology appraisal guidance
TBC
Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]
Technology appraisal guidance
TBC
Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor [ID6213]
Technology appraisal guidance
TBC
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]
Technology appraisal guidance
TBC
Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma [ID6325]
Technology appraisal guidance
10 September 2025
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]
Technology appraisal guidance
TBC
Avapritinib for treating advanced systemic mastocytosis ID3770
Technology appraisal guidance
TBC
Current page
1
2
3
…
13
Page
1
of
13
Next page
Results per page
10
25
50
All
Back to top